Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy.

Perna F, Sadelain M.

Transl Cancer Res. 2016 Aug;5(Suppl 2):S221-S225. doi: 10.21037/tcr.2016.08.15. No abstract available.

2.

Targeting human SET1/MLL family of proteins.

Vedadi M, Blazer L, Eram MS, Barsyte-Lovejoy D, Arrowsmith CH, Hajian T.

Protein Sci. 2017 Apr;26(4):662-676. doi: 10.1002/pro.3129. Epub 2017 Mar 6. Review.

3.

JAK2 V617F mutation, multiple hematologic and non-hematologic processes: an association?

Liu KG, Verma A, Derman O, Kornblum N, Janakiram M, Braunschweig I, Battini R.

Biomark Res. 2016 Oct 19;4:19. eCollection 2016.

4.

Hypoxia inducible factor-1α regulates a pro-invasive phenotype in acute monocytic leukemia.

Migliavacca J, Percio S, Valsecchi R, Ferrero E, Spinelli A, Ponzoni M, Tresoldi C, Pattini L, Bernardi R, Coltella N.

Oncotarget. 2016 Aug 16;7(33):53540-53557. doi: 10.18632/oncotarget.10660.

5.

Philadelphia chromosome-negative acute myeloid leukemia with 11q23/MLL translocation in a patient with chronic myelogenous leukemia.

Jaitly V, Wang W, Hu S.

Stem Cell Investig. 2015 Jul 1;2:13. doi: 10.3978/j.issn.2306-9759.2015.06.01. eCollection 2015.

6.

Bilateral orbital myeloid sarcoma preceding acute myeloid leukemia in an adult: a case report and review of the literature.

Vera-Aguilera J, Mukarram O, Nutalapati P, Mok M, Bulumulle A, Vera-Aguilera C.

J Med Case Rep. 2016 Feb 4;10:31. doi: 10.1186/s13256-015-0778-2. Review.

7.

Emerging therapeutic drugs for AML.

Stein EM, Tallman MS.

Blood. 2016 Jan 7;127(1):71-8. doi: 10.1182/blood-2015-07-604538. Epub 2015 Dec 10. Review.

8.

Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.

Chen CW, Armstrong SA.

Exp Hematol. 2015 Aug;43(8):673-84. doi: 10.1016/j.exphem.2015.05.012. Epub 2015 Jun 25. Review.

9.

Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis.

Wang W, Tang G, Cortes JE, Liu H, Ai D, Yin CC, Li S, Khoury JD, Bueso-Ramos C, Medeiros LJ, Hu S.

J Hematol Oncol. 2015 Apr 8;8:32. doi: 10.1186/s13045-015-0128-2.

10.

Cellular Reprogramming Allows Generation of Autologous Hematopoietic Progenitors From AML Patients That Are Devoid of Patient-Specific Genomic Aberrations.

Salci KR, Lee JH, Laronde S, Dingwall S, Kushwah R, Fiebig-Comyn A, Leber B, Foley R, Dal Cin A, Bhatia M.

Stem Cells. 2015 Jun;33(6):1839-49. doi: 10.1002/stem.1994.

11.

Acquired dependence of acute myeloid leukemia on the DEAD-box RNA helicase DDX5.

Mazurek A, Park Y, Miething C, Wilkinson JE, Gillis J, Lowe SW, Vakoc CR, Stillman B.

Cell Rep. 2014 Jun 26;7(6):1887-99. doi: 10.1016/j.celrep.2014.05.019. Epub 2014 Jun 5.

12.

Hypermethylation and down-regulation of DLEU2 in paediatric acute myeloid leukaemia independent of embedded tumour suppressor miR-15a/16-1.

Morenos L, Chatterton Z, Ng JL, Halemba MS, Parkinson-Bates M, Mechinaud F, Elwood N, Saffery R, Wong NC.

Mol Cancer. 2014 May 24;13:123. doi: 10.1186/1476-4598-13-123.

13.

Mechanisms of mixed-lineage leukemia.

Muntean AG.

Int J Hematol Oncol. 2013 Jun 1;2(3):207-217.

14.

Molecular characterization and clinical impact of t(11;15)(q23;q14-15) MLL-CASC5 rearrangement.

Yang JJ, Park TS, Lee ST, Seo JY, Oh SH, Cho EH, Strehl S, Mühlegger N, Dworzak MN, Zuna J, Pospisilova D, Meyer C, Marschalek R, Kim HJ, Kim SH.

Haematologica. 2014 Jan;99(1):e11-3. doi: 10.3324/haematol.2013.095638. No abstract available.

15.

Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis.

Ballabio E, Milne TA.

Cancers (Basel). 2012 Sep 10;4(3):904-44. doi: 10.3390/cancers4030904.

16.

Visualising the cross-level relationships between pathological and physiological processes and gene expression: analyses of haematological diseases.

Ono M, Tanaka RJ, Kano M, Sugiman T.

PLoS One. 2013;8(1):e53544. doi: 10.1371/journal.pone.0053544. Epub 2013 Jan 2.

17.

New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461.

Walker A, Mrózek K, Kohlschmidt J, Rao KW, Pettenati MJ, Sterling LJ, Marcucci G, Carroll AJ, Bloomfield CD; Alliance for Clinical Trials in Oncology.

Genes Chromosomes Cancer. 2013 Apr;52(4):385-401. doi: 10.1002/gcc.22036. Epub 2012 Dec 10.

18.

Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML.

Borate U, Absher D, Erba HP, Pasche B.

Expert Rev Anticancer Ther. 2012 Oct;12(10):1289-97. doi: 10.1586/era.12.116.

19.

Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation.

Chen Y, Kantarjian H, Pierce S, Faderl S, O'Brien S, Qiao W, Abruzzo L, de Lima M, Kebriaei P, Jabbour E, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Cortes J, Ravandi F.

Leukemia. 2013 Apr;27(4):836-42. doi: 10.1038/leu.2012.319. Epub 2012 Nov 8.

Supplemental Content

Support Center